Durvalumab in Treating Patients With Primary Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis

  • STATUS
    Not Recruiting
  • participants needed
    10
  • sponsor
    Northwestern University
Updated on 23 January 2021
cancer
hysterectomy
myelofibrosis
bilateral oophorectomy
neutrophil count
medi4736
essential thrombocythemia
thrombocytosis
polycythemia
thrombocythemia

Summary

The main purpose of this investigational research study is to determine how safe and tolerable the study drug, MEDI4736 (Durvalumab), is in patients with myelofibrosis (MF). The study drug belongs to a group of drugs called immune checkpoint inhibitors, which have shown promise in other forms of cancer, such as melanoma and lung cancer. One of the effects that this drug has is to activate the patient's own natural immune system. The purpose of this study is to examine the safety and tolerability of the study drug, to study how effective it is at treating patients with myelofibrosis, and to explore how certain markers in the patient's blood and/or bone marrow may be affected by the study drug.

Description

PRIMARY OBJECTIVES: I. To determine the safety profile of anti-programmed cell death 1 ligand 1 (PDL1) therapy in patients with myelofibrosis. SECONDARY OBJECTIVES: I. Changes in MF symptom burden. II. Changes in spleen size. III. Blood and/or bone marrow samples. TERTIARY OBJECTIVES: I. To determine the rate of lymphocyte subset response to anti-PDL1 therapy, as measured by the percent increase in cluster of differentiation (CD)4+CD25+PD-L1+ T-lymphocytes and CD4+CD62L+CD127+ T lymphocytes in post-treatment peripheral blood samples. II. To characterize changes in the cytokine profile in response to anti-PDL1 therapy. III. To measure soluble PDL1 by enzyme-linked immunosorbent assay (ELISA) in post-treatment blood and/or bone marrow samples and programmed cell death-1 (PD1)/PDL1 by immunohistochemistry on bone marrow samples and correlate with treatment response. OUTLINE: Patients receive durvalumab intravenously (IV) over approximately 1 hour on day 1. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients with stable disease (SD), no new inter-current illness, and no unacceptable toxicity, may continue treatment beyond 3 courses. Patients will be followed every 3 months for up to two years starting from Day 1.

Details
Condition Myelosclerosis with myeloid metaplasia
Treatment laboratory biomarker analysis, durvalumab
Clinical Study IdentifierNCT02871323
SponsorNorthwestern University
Last Modified on23 January 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note